³Ô¹Ï±¬ÁÏ Announces My³Ô¹Ï±¬ÁÏ to Enable
Patient-Centric Clinical Trials
Multichannel patient portal will help clinical research sites conduct virtual patient visits
eSource capability will enable paperless clinical trials
PLEASANTON, CA ¡ª May 19, 2020 ¡ª ³Ô¹Ï±¬ÁÏ Systems (NYSE:VEEV) today announced My³Ô¹Ï±¬ÁÏ for Patients, a new application for clinical research sites. With capabilities for virtual visits, patient adherence, ePRO, eConsent, eSource and an easy to use patient portal, My³Ô¹Ï±¬ÁÏ for Patients will make it easier for clinical research sites to deliver a patient-centric and paperless clinical trial experience for patients and sponsors. My³Ô¹Ï±¬ÁÏ for Patients is free for clinical research sites and integrates seamlessly with ³Ô¹Ï±¬ÁÏ SiteVault.
Doctors can conduct virtual visits and make it easier for patients to participate in clinical trials.
¡°There is a pressing need for clinical solutions that reduce the burden on patients participating in trials and make study execution easier for sites,¡± said Jessica Collins, program director for investigator-initiated clinical trials at Vanderbilt University Medical Center. ¡°Having the ability to conduct parts of a study remotely is key to a better patient experience and speeding study conduct. It¡¯s a crucial shift for the industry and I appreciate the innovation ³Ô¹Ï±¬ÁÏ is bringing to this important area.¡±
My³Ô¹Ï±¬ÁÏ for Patients enables patients, doctors, and clinical research coordinators to collaborate remotely with advanced audio and video capabilities, reducing the need for in-person visits. Clinical researchers can collect and record patient data electronically; make it more convenient for patients to report on treatment outcomes; easily share information electronically and get patient consent; and help patients take medications and adhere to their treatment regimens.
¡°COVID-19 created even greater urgency for clinical trials to become more virtual and deliver a safe, convenient patient experience,¡± said Henry Levy, general manager of Vault CDMS, site, and patient solutions at ³Ô¹Ï±¬ÁÏ. ¡°Enabling home-based trial visits with My³Ô¹Ï±¬ÁÏ for Patients can advance the move to more patient-centric and paperless trials. We are excited to partner with the industry to help improve the clinical trial process for sponsors, sites, and patients.¡±
Sites will have the flexibility to use My³Ô¹Ï±¬ÁÏ for Patients with ³Ô¹Ï±¬ÁÏ SiteVault and ³Ô¹Ï±¬ÁÏ Vault Clinical applications, as well as third-party clinical applications. My³Ô¹Ï±¬ÁÏ for Clinical Trials is planned for availability in December 2020.
My³Ô¹Ï±¬ÁÏ for Patients is part of the ³Ô¹Ï±¬ÁÏ Clinical Network, a set of solutions that brings together sponsors, sites, and patients to accelerate clinical research. In addition to My³Ô¹Ï±¬ÁÏ, ³Ô¹Ï±¬ÁÏ today announced ³Ô¹Ï±¬ÁÏ Site Connect, a new application that connects sponsors and clinical research sites during trials. Together with ³Ô¹Ï±¬ÁÏ Vault Clinical Suite, ³Ô¹Ï±¬ÁÏ is the first and only company providing solutions that help sponsors, sites, and patients share and view information during a clinical trial. For more information on how ³Ô¹Ï±¬ÁÏ will enable patient-centric trials, contact info@veeva.com.
Additional Information
Connect with ³Ô¹Ï±¬ÁÏ on LinkedIn:
Follow @veevasystems on Twitter:
Like ³Ô¹Ï±¬ÁÏ on Facebook:
About ³Ô¹Ï±¬ÁÏ Systems
³Ô¹Ï±¬ÁÏ Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, ³Ô¹Ï±¬ÁÏ serves more than 850 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. ³Ô¹Ï±¬ÁÏ is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of ³Ô¹Ï±¬ÁÏ¡¯s products and services, the results from use of ³Ô¹Ï±¬ÁÏ¡¯s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon ³Ô¹Ï±¬ÁÏ¡¯s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent ³Ô¹Ï±¬ÁÏ¡¯s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and ³Ô¹Ï±¬ÁÏ disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect ³Ô¹Ï±¬ÁÏ¡¯s financial results are included under the captions, ¡°Risk Factors¡± and ¡°Management¡¯s Discussion and Analysis of Financial Condition and Results of Operations,¡± in the company¡¯s filing on Form 10-K for the period ended January 31, 2020. This is available on the company¡¯s website at veeva.com under the Investors section and on the SEC¡¯s website at . Further information on potential risks that could affect actual results will be included in other filings ³Ô¹Ï±¬ÁÏ makes with the SEC from time to time.
###
Contact:
³Ô¹Ï±¬ÁÏ Systems
pr@veeva.com
Deivis Mercado
³Ô¹Ï±¬ÁÏ Systems
925-226-8821
deivis.mercado@veeva.com